Impacto da análise molecular da mutação JAK2V617F no diagnóstico de neoplasias mieloproliferativas crônicas de acordo com os critérios da OMS 2016

Impacto da análise molecular da mutação JAK2V617F no diagnóstico de neoplasias mieloproliferativas crônicas de acordo com os critérios da OMS 2016

Show other versions (2)

As neoplasias mieloproliferativas (NMPs) são um grupo de doenças derivadas de uma transformação clonal de célula tronco hematopoiéticas no qual a linhagem celular mielóide é predominantemente expandida no sangue periférico. As NMPs Philadelphia-negativas incluem policitemia vera (PV), trombocitemia...

Full description

Bibliographic Details
Main Author:	Pedrazzani, Fabiane Spagnol
Other Authors:	Scroferneker, Maria Lucia
Format:	Others
Language:	Portuguese
Published:	2017
Subjects:	Policitemia vera Trombocitemia essencial Mielofibrose primária Myeloproliferative neoplasms Polycythemia vera Essential thrombocythaemia Primary myelofibrosis JAK2 JAK2V617F
Online Access:	http://hdl.handle.net/10183/157653

Similar Items

Impacto da análise molecular da mutação JAK2V617F no diagnóstico de neoplasias mieloproliferativas crônicas de acordo com os critérios da OMS 2016
by: Pedrazzani, Fabiane Spagnol
Published: (2017)

Impacto da análise molecular da mutação JAK2V617F no diagnóstico de neoplasias mieloproliferativas crônicas de acordo com os critérios da OMS 2016
by: Pedrazzani, Fabiane Spagnol
Published: (2017)

A mutação JAK2 V617F e as síndromes mieloproliferativas JAK2 V617F mutation and the myeloproliferative disorders
by: Bárbara C. R. Monte-Mór, et al.
Published: (2008-01-01)

Estudo do perfil genético de pacientes com Neoplasias Mieloproliferativas (NMP) cromossomo Filadélfia negativo
by: Mariana Marchiani
Published: (2016)

Estudo do perfil genético de pacientes com Neoplasias Mieloproliferativas (NMP) cromossomo Filadélfia negativo
by: Marchiani, Mariana
Published: (2016)

Neoplasias mieloproliferativas: revisão dos critérios diagnósticos e dos aspectos clínicos Myeloproliferative neoplasms: a review of diagnostic criteria and clinical aspects
by: Maria de Lourdes L. F. Chauffaille
Published: (2010-01-01)

Estudo comparativo entre diferentes metodologias na detecção da mutação JAK2V617F em Neoplasias Mieloproliferativas Crônicas BCR-ABL1 negativo
by: Alline Didone
Published: (2015)

Estudo comparativo entre diferentes metodologias na detecção da mutação JAK2V617F em Neoplasias Mieloproliferativas Crônicas BCR-ABL1 negativo
by: Didone, Alline
Published: (2015)

Clinical meaning of JAK2 V617F mutation in chronic myeloproliferative disorders – the first experience
by: Joško Vučković, et al.
Published: (2006-10-01)

Introducción del estudio molecular de la mutación JAK2V617F en neoplasias mieloproliferativas clásicas BCR-ABL negativas
by: Ana María Amor-Vigil, et al.

JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
by: Bárbara da Costa Reis Monte-Mór, et al.
Published: (2007-03-01)

Rapid identification of heterozygous or homozygous JAK2V617F mutations in myeloproliferative neoplasms using melting curve analysis
by: Ching-Liang Ho, et al.
Published: (2012-01-01)

Evaluation of JAK2V617F Mutation Prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: B Bahar, et al.
Published: (2009-11-01)

Evaluation of JAK2V617F mutation prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: H Ghafari, et al.
Published: (2009-09-01)

Clinical and laboratory presentations of Janus Kinase II-positive patients in Saudi population
by: H Malhan, et al.
Published: (2014-01-01)

Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance
by: Saeid Shahrabi, et al.
Published: (2018-10-01)

Molecular pathogenesis of the myeloproliferative neoplasms
by: Graeme Greenfield, et al.
Published: (2021-06-01)

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data
by: Loscocco GG, et al.
Published: (2020-12-01)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
by: Giuseppe G. Loscocco, et al.
Published: (2021-08-01)

Biology of Myeloproliferative Malignancies
by: AL Melikyan, et al.
Published: (2016-07-01)

EVALUATION OF THE CORRELATION BETWEEN JAK2V617F, LEUCOCYTOSIS AND THROMBOGENIC RISK IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
by: Antonio Antonov, et al.
Published: (2018-07-01)

Data‐driven analysis of JAK2V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms
by: Rasmus K. Pedersen, et al.
Published: (2020-03-01)

CORRELATION BETWEEN JAK2V617F MUTATIONAL BURDEN AND THE DEGREE OF ANGIOGENESIS IN THE BONE MARROW OF BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
by: Liana Gercheva, et al.
Published: (2014-09-01)

Philadelphia-negative chronic myeloproliferative neoplasms
by: Rosane Isabel Bittencourt, et al.
Published: (2012-01-01)

Low <i>Jak2</i> V617f Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional <i>Calr</i> or <i>Mpl</i> Gene Mutations
by: Tatiana V. Makarik, et al.
Published: (2021-04-01)

JAK2 Negative Polycythemia Vera
by: Geetha J P., et al.
Published: (2010-07-01)

EXTENSION OF 2016 WORLD HEALTH ORGANIZATION (WHO) CLASSIFICATION INTO A NEW SET OF CLINICAL, LABORATORY, MOLECULAR, AND PATHOLOGICAL CRITERIA FOR THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS: FROM DAMESHEK TO VAINCHENKER, GREEN, AND KRALOVICS
by: Jan Jacques Michiels, et al.
Published: (2017-06-01)

Cluster-Like Headache Revealing Polycythemia Vera: A Case Report
by: Cyprian Popescu
Published: (2020-06-01)

The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry
by: Chris Varghese, et al.
Published: (2021-04-01)

A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate
by: Anders Lindholm Sørensen, et al.
Published: (2016-01-01)

Detection of JAK2V617F tyrosine kinase mutation and estimation of serum erythropoietin in blood donors who have high hematocrit
by: Haythem A. AL-Rubaie, et al.
Published: (2015-01-01)

Recurrent Episodes of Angioedema as Presenting Feature of JAK2-Positive Myeloproliferative Disorder Consistent with Polycythaemia Vera
by: Laith Al-Azrai, et al.
Published: (2021-07-01)

The Prevalence of <i>TET2</i> Gene Mutations in Patients with <i>BCR</i>-<i>ABL</i>-Negative Myeloproliferative Neoplasms (MPN): A Systematic Review and Meta-Analysis
by: Yuh Cai Chia, et al.
Published: (2021-06-01)

Polycythemia Vera: New Diagnostic Concept and Its Types
by: AM Kovrigina, et al.
Published: (2016-04-01)

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
by: Andrew T. Kuykendall, et al.
Published: (2020-08-01)

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
by: M.E. Bjørn, et al.
Published: (2014-01-01)

Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN)
by: Razan Hayati Zulkeflee, et al.
Published: (2021-07-01)

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition
by: Leslie Padrnos, et al.
Published: (2020-11-01)

Policitemia Vera en la era del Jak: breve análisis del diagnóstico después de su introducción
by: Norma Fernández Delgado, et al.

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
by: Blum S, et al.
Published: (2016-09-01)